Rational use of cetuximab in the treatment of advanced non-small cell lung cancer

Figures & data

Table 1 Trials evaluating use of cetuximab in combination with chemotherapy in first-line setting in Stage IIIb/IV NSCLC

Author	Phase	n	Chemotherapya	Results for cetuximab group
Thienelt et al^Citation77	I/IIa	31	Cb AUC 6 T 225 mg/m^2 (every 3 wk)	Median OS 11 mos Median TTP 5 mos
Robert et al^Citation78	I/IIa	35	Cb AUC 5 Gem 1000 mg/m^2 (d1,8) (every 3 wk)	Median OS 320 days Median TTP 165 days
Butts et al^Citation79	II	131	Cb AUC 5 or CDDP 75 mg/m^2 Gem 1000 mg/m^2 (d1,8) (every 3 wk)	Median OS 11.99 mos Median PFS 5.09 mos
Spigel et al^Citation80	II	27	Gem 1000 mg/m^2 IV Doc 30 mg/m^2 IV days 1, 8 (every 3 wk)	Median OS NR Median PFS NR
Belani et al^Citation81	II	80	Cb AUC 6 Docetaxel 75 mg/m^2 (every 3 wk)	Median OS 10.3 mos Median PFS 4.6 mos
Borghaei et al^Citation82	II	53	Cb AUC 6 T 100 mg/m^2 (d1,8,15) (every 4 wk)	Median OS 13.8 mos Median TTP 5.5 mos
Bradford et al^Citation85	II	57	Cb AUC 6	Pending
Lilenbaum et al^Citation86 (PS 2 patients)	II	55	Doc (30 mg/m^2 wkly for 3 wk) or Bortezomib (1.6 mg/m^2 wkly for 3 wk) (every 4 wk)	Median OS 3.8 vs 3.3 mos Median PFS 3.1 vs 1.8 mos
Rosell et al^Citation87	II	86	CDDP 80 mg/m^2 Vinorlebine 25 mg/m^2 (d1,8) (every 3 wk)	Median OS 8.3 mos Median PFS 5 mos
Pirker et al^Citation71,Citation88	III	1125	CDDP 80 mg/m^2 Vinorlebine 25 mg/m^2 (d1,8) (every 3 wk)	Median OS 11.3 mos Median PFS NR
Lynch et al^Citation89	III	676	Cb AUC 6 with T (225 mg/m^2) or Dose (75 mg mg/m^2) (every 3 wk)	Median OS NR Median PFS 4.4 mos

a All evaluated chemotherapy in addition to cetuximab (400 mg/m² iv during the first week followed by 250 mg/m² iv weekly) unless otherwise specified.

Abbreviations: Cb, carboplatin; T, paclitaxel; CDDP, cisplatin; Gem, gemcitabine; AUC, area under the curve; Doc, docetaxel; OS, overall survival; PFS, progression-free survival; mos, months; wk, weeks; NR, not reported; TTP, time to progression.

Table 2 Trials evaluating the use of cetuximab with chemotherapy in relapsed/refractory in Stage IIIb/IV NSCLC

Author	Phase	n	Treatment	Results
Hanna et al^Citation90	II	66	Weekly cetuximab	ORR 4.5% Median OS 8.9 mos Median TTP 2.3 mos
Jalal et al^Citation91	I/IIa	23	Weekly cetuximab + Pem (750 mg/m^2 iv every 3 weeks)	ORR 9.5% Median TTP 5.5 mos
Kim et al^Citation92	II	47	Weekly cetuximab + Doc (75 mg/m^2 iv every 3 weeks)	Median TTP 89 days

Abbreviations: OS, overall survival; TTP, time to progression; Pem, pemetrexed; ORR, overall response rate.

ThieneltCDBunnPAJrHannaNMulticenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancerJ Clin Oncol2005238786879316246975

 PubMed Web of Science ®Google Scholar

RobertFBlumenscheinGHerbstRSPhase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancerJ Clin Oncol2005239089909616301597

 PubMed Web of Science ®Google Scholar

ButtsCABodkinDMiddlemanELRandomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancerJ Clin Oncol2007255777578418089875

 PubMed Web of Science ®Google Scholar

SpigelDGrecoFBurrisHDocetaxel, gemcitabine, and cetuximab in untreated advanced non-small cell lung cancer: P3–144. 12th World Conference on Lung Cancer; 2007 September 2–6J Thorac OncolSeoul, Korea: 20072(8)Suppl 4S740S741

 Google Scholar

BelaniCPSchreederMTSteisRGCetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 studyCancer20081132512251718816622

 PubMed Web of Science ®Google Scholar

BorghaeiHLangerCJMillensonMPhase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017J Thorac Oncol200831286129218978564

 PubMed Web of Science ®Google Scholar

BradfordDSocinskiMLaRoccaRPhase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings Part IJ Clin Oncol20072518SJune 20 Suppl:Abstract 18005.

 Google Scholar

LilenbaumRWangXGuLPhase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2-CALGB 30402. ASCO Annual Meeting Proceedings Part IJ Clin Oncol20072518SJune 20 Suppl:Abstract 7595.

 Google Scholar

RosellRRobinetGSzczesnaARandomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancerAnn Oncol20081936236917947225

 PubMed Web of Science ®Google Scholar

PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet20093731525153119410716

 PubMed Web of Science ®Google Scholar

PirkerRSzczesnaAvon PawelJFLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)J Clin Oncol200826(May 20 Suppl):Abstract 3.

 Web of Science ®Google Scholar

LynchTTaralPLukeDA randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC): B3–03J Thorac Oncol20072(8)Suppl 4S340S341

 Web of Science ®Google Scholar

HannaNLilenbaumRAnsariRPhase II trial of cetuximab in patients with previously treated non-small-cell lung cancerJ Clin Oncol2006245253525817114658

 PubMed Web of Science ®Google Scholar

JalalSWaterhouseDEdelmanMPemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): A phase I–IIa dose-ranging study from the Hoosier Oncology Group. ASCO Annual Meeting Proceedings Part IJ Clin Oncol20072518SJune 20 Suppl:Abstract 7698.

 Google Scholar

KimESMauerAMWilliamWNJrA phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall-cell lung cancerCancer2009

 Web of Science ®Google Scholar